514 related articles for article (PubMed ID: 15870437)
1. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
[TBL] [Abstract][Full Text] [Related]
2. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
3. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
Bessho A; Ueoka H; Kiura K; Tabata M; Sunami K; Katayama Y; Yamane H; Hiraki A; Harada M
Anticancer Res; 1999; 19(1B):693-8. PubMed ID: 10216478
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F
Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
[TBL] [Abstract][Full Text] [Related]
5. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
6. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
[TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
9. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
11. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
[TBL] [Abstract][Full Text] [Related]
12. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
15. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.
Woll PJ; Thatcher N; Lomax L; Hodgetts J; Lee SM; Burt PA; Stout R; Simms T; Davies R; Pettengell R
J Clin Oncol; 2001 Feb; 19(3):712-9. PubMed ID: 11157022
[TBL] [Abstract][Full Text] [Related]
16. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
Crawford J; George M
Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
[TBL] [Abstract][Full Text] [Related]
17. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics.
Sculier JP; Paesmans M; Lecomte J; Van Cutsem O; Lafitte JJ; Berghmans T; Koumakis G; Florin MC; Thiriaux J; Michel J; Giner V; Berchier MC; Mommen P; Ninane V; Klastersky J;
Br J Cancer; 2001 Nov; 85(10):1444-51. PubMed ID: 11720426
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Johnson PW; Muers MF; Peake MD; Poulter KM; Gurney EM; Napp VV; Hepburn PM; Brown JM
Br J Cancer; 2001 Jan; 84(1):19-24. PubMed ID: 11139307
[TBL] [Abstract][Full Text] [Related]
20. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
